🔍
GLP-3R Pro Series 10 mg research peptide vial, lot Black Cap, 99.62% purity

GLP-3R – Pro

Pro Series
A synthetic triple agonist peptide at the GLP-1, GIP and glucagon receptors
CAS 2381089-83-2C₂₂₁H₃₄₂N₄₆O₆₈Approximately 4731.34 g/molLinear peptideLyophilized powder

Price range: $129.00 through $2,331.00

Ships from lot Black Cap · 10 mg vial · 99.62% purity · Freedom Diagnostics See the COA
Why the Pro Series costs more
  • Synthesized in the USA. Domestic ground and air only, no ocean freight.
  • Released only above 99% HPLC purity.
  • Its own lot and its own published certificate.
How the Pro Series is made and tested
Ships from Austin, TexasUnited States only
Tested by an outside labNever in-house
Every lot publishedIncluding rejected lots
Same-day dispatchOn orders before 2pm ET
SKU: N/A Category: Tags: ,
BATCH
VERIFICATION
LOT NUMBER
Black Cap
10 mg vial
IDENTITY
Confirmed
CHROMATOGRAPHIC PURITY
99.62%
NET CONTENT
9.42 mg
Analytical characterization

Every result against its specification.

Lot Black Cap · 10 mg vial · Freedom Diagnostics · reported 30 August 2026 . The bar shows where the reported result falls against Astramide’s published release criterion. The notch marks the criterion.
Within criterion Above criterion Not on this COA
Test
Method
Criterion
Result
Result vs criterion
Status
Identity
LC-MS
LC-MS match to the labelled compound
Confirmed
WITHIN SPEC
Chromatographic purity
HPLC-UV
at or above 98.0%
99.62%
95 at or above 98.0% 100
WITHIN SPEC
Net content
HPLC-UV
9.42 mg
80 120
REPORTED
Endotoxin
LAL, USP <85>
below the 0.05 EU/mL assay sensitivity
Pass, 2 of 2 at ≤0.05 EU/mL
WITHIN SPEC
Appearance
Visual
white lyophilized powder
White Lyophilized Powder
WITHIN SPEC
Values are reported per vial unless otherwise noted. Every figure here is taken from the batch Certificate of Analysis and nothing else.
Certificate of Analysis
GLP-3R - Pro · Lot Black Cap · 10 mg vial · Lab No. 2608270453
Download Full screen
Your browser cannot display the report inline. Open the PDF.
Freedom Diagnostics · 1 page · served inline, not a screenshot
Quick reference

How to read this report

Same six keys on every Astramide product page. Only the values change.
1Lot numberMatch it to the number printed on your vial. If they differ, this report is not for your vial.
2IdentityMass spectrometry confirms the molecule is the one on the label. It conforms or it does not. There is no partial result.
3Chromatographic purityThe share of the material that is the target peptide. A purity figure quoted without a method is not a purity figure.
4Net contentHow much peptide is in the vial, as measured by the laboratory. A different question from purity.
5EndotoxinMeasured against a ceiling, not a floor. Sensitivity differs by laboratory, so results are not compared across labs.
6Laboratory, method, dateWho ran it, on what instrument, and when. A report with no named laboratory or no date is not a report.
Molecular profile

GLP-3R - Pro, in structural terms.

GLP-3R - Pro molecular structure
Sequence
Modified 39-residue sequence: Y–Aib–QGTFTSDYSI–2-Me-Leu–LDK–[Lys(AEEA-γGlu-C20 diacid)]–AQAibAFIEYLLEGGPSSGAPPPS-NH₂ This is not a simple conventional amino-acid sequence because the molecule incorporates Aib residues, α-methyl-leucine, a modified lysine carrying a lipid-linked side chain, and a C-terminal serinamide. KEGG reports the 39-residue backbone and identifies the molecule as a modified peptide.
Molecular formula
C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight
Approximately 4731.34 g/mol
CAS number
2381089-83-2
Structure type
Linear peptide
Primary molecular target
GLP-1 Receptor (GLP-1R) / GIP Receptor (GIPR) / Glucagon Receptor (GCGR) All three are established molecular targets of the reference compound.
Physical form
Lyophilized powder
PubChem CID
171390338

GLP-3R is a synthetic 39-residue modified and lipidated peptide engineered for multi-receptor activity. Its structure incorporates noncanonical amino-acid modifications and a lipid-containing side chain. These modifications differentiate the molecule from naturally occurring GLP-1, GIP, and glucagon peptides and contribute to its distinctive triple-receptor pharmacology. IUPHAR/BPS describes the reference compound as a lipidated, modified peptide targeting GCGR, GIPR, and GLP-1R.KEGG reports this molecular formula, a molecular weight of 4731.34 and an exact mass of 4728.4718 for the reference modified peptide.

Research profile

Where GLP-3R - Pro appears in the literature.

Metabolic Research; Endocrinology; Peptide Biology; GPCR Pharmacology; Receptor Signaling; Molecular Pharmacology
Research applications
  • Published experimental use of multi-receptor incretin peptide analogues includes:
  • Receptor binding and activation assays across individual class B receptors
  • Receptor selectivity and potency ratio determination for multi-agonist scaffolds
  • cAMP accumulation and β-arrestin recruitment profiling
  • Cryo-electron microscopy of peptide–receptor–G protein complexes
  • Structure–activity studies using substituted and truncated analogues
  • Analytical characterisation of synthetic peptide analogues by HPLC and high-resolution mass spectrometry
  • These areas describe experimental research contexts and do not establish therapeutic efficacy or safety in humans.
Experimental systems
  • GLP-1R-expressing cell systems
  • GIPR-expressing cell systems
  • GCGR-expressing cell systems
  • Receptor-transfected cellular models
  • cAMP reporter systems
  • Pancreatic islet models
  • Adipocyte models
  • Hepatic metabolic models
Specific assays
  • Assay formats reported in this literature include:
  • Competition radioligand and fluorescent ligand binding assays
  • HTRF and BRET cAMP accumulation assays
  • β-arrestin recruitment and receptor internalisation assays
  • Reporter-gene assays under cAMP-responsive promoters
  • Concentration–response profiling across receptor panels
  • Single-particle cryo-electron microscopy structure determination
  • Reversed-phase HPLC with UV and mass spectrometric detection
Measured endpoints
  • Endpoints reported in published research on multi-receptor peptide analogues include:
  • Binding affinity (Ki) and functional potency (EC50) at each receptor in the panel
  • Receptor selectivity ratios across the target set
  • Intracellular cAMP accumulation relative to reference ligand
  • β-arrestin recruitment and receptor trafficking behaviour
  • Maximal response and relative efficacy per receptor
  • Chromatographic purity and mass accuracy for synthetic preparations
  • Research use only. Not for human or animal consumption.
Pcs

Single Vial, Pack of 10
Strength

10mg, 20mg, 30mg
Mechanism and research context

What has been studied, and in what systems.

In preclinical and laboratory research models, GLP-3R has been examined across metabolic, endocrine, and systemic research systems. Research focus includes:

GLP-1 receptor signaling pathways
GIP receptor activity models
Glucagon receptor interactions
Multi-hormone signaling mechanisms

These observations are limited to controlled experimental environments and support ongoing laboratory investigations.

These are published research systems. They do not describe approved clinical applications, and they do not establish efficacy or safety in humans.

Cited literature

Li W et al., 2024. Cell Discov. PMID 39019866. https://pubmed.ncbi.nlm.nih.gov/39019866/

Brubaker PL et al., 2002. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channels. PMID 12529935. https://pubmed.ncbi.nlm.nih.gov/12529935/

Novikoff A et al., 2021. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab. PMID 33556643. https://pubmed.ncbi.nlm.nih.gov/33556643/

Evidence level
Published preclinical and early experimental research. This compound appears in the published receptor-pharmacology literature, predominantly in in-vitro binding and animal-model studies. This describes the evidence base around the molecule and does not imply approval or established efficacy.
Handling and storage

As supplied. Lyophilized powder in a sealed vial. Held in laboratory-rated freezers from arrival to shipment.

Handling. For qualified professionals in controlled laboratory environments, following validated laboratory procedures.

Frequently asked questions

About this compound and its batch data.

What is GLP-3R Pro?

GLP-3R is a synthetic, 39-residue lipidated peptide that acts as an agonist at three class B receptors: GLP-1R, GIPR and GCGR. CAS 2381089-83-2, formula C221H342N46O68, about 4731 g/mol. GLP-3R Pro is the USA-made Pro Series lot, supplied as a lyophilized powder for laboratory research use only.

What has GLP-3R been examined for in published research?

Li et al. (2024) solved cryo-EM structures of the peptide bound to GLP-1R, GIPR and GCGR, each in complex with Gs protein, and examined its activation of the three receptors in cell-based assays (Cell Discov, PMID 39019866). This work is pre-clinical and structural. Astramide makes no claim about outcomes in humans.

What purity does the current GLP-3R Pro lot reach?

Lot Black Cap returned 99.62% purity by HPLC-UV at Freedom Diagnostics, accession 2608270453, reported 30 August 2026. Identity was confirmed by LC-MS. Pro lots are released only above 99%. To verify the certificate independently, quote the accession number to the laboratory. The full document is published on this page.

How much GLP-3R is in a GLP-3R Pro vial?

For the 10 mg vial, the laboratory measured 9.42 mg. That is 94.2% of the label claim. Astramide publishes the measured figure rather than the label claim, whether it falls above or below. The 20 mg and 30 mg vials are filled from the same synthesis batch. The certificate reports the 10 mg vial.

How is Astramide's GLP-3R Pro tested?

Freedom Diagnostics, an outside laboratory, tested lot Black Cap for identity by LC-MS, purity by HPLC-UV, net content, endotoxin by LAL under USP <85>, and appearance. Heavy metals, microbial and residual-solvent tests were not performed on this lot. Astramide never tests in-house. The testing process explains what each method measures.

How should GLP-3R Pro be stored for research use?

Hold the lyophilized powder at -20°C, sealed and protected from light and moisture. Avoid repeated temperature cycling. Astramide holds every lot in laboratory-rated freezers from arrival to shipment. Follow the handling procedures validated for your laboratory.

What is the difference between research-grade and pharmaceutical-grade GLP-3R?

These are separate classifications. Research-grade material is supplied for laboratory research use only. It is not for human or animal consumption. Pharmaceutical-grade is an FDA classification for drugs made for human use. Astramide supplies research-grade material only.

What is the difference between GLP-3R and GLP-3R Pro?

GLP-3R Pro is part of the Astramide Pro Series. It is American-made, synthesized in the USA, and moves by domestic ground and air only, with no ocean freight. It is released under its own lot, and only when HPLC purity measures above 99%. The full certificate for each lot is published on this page. The standard GLP-3R is released under separate lots with separate certificates. Its current lot is 2026/02.

Research use only

This product is intended strictly for in-vitro laboratory research conducted by qualified professionals. It is not intended for human or animal consumption, clinical use, or therapeutic application. The statements on this page have not been reviewed by the FDA. These research peptides are not intended to diagnose, treat, cure, or prevent any disease. Research Use Only.

COA library Every lot we have tested Search by batch number. Past lots stay published. How we test The analytical panel What each method measures and the criterion each lot must meet. Open Lab Send us your peptides Any vendor. Same lab. Your own Certificate of Analysis.
Ships from Austin, TexasUSPS or UPS, your choice
United States onlyFree shipping at $150 and over
Optional shipping insuranceAdded at checkout
Replacement or store creditOn approved claims. See refund policy.

Related products